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Abstract 
Outcome of variceal bleeding (VB) in patients with hepatocellular carcinoma (HCC) is 
unknown. We compared outcomes after VB in patients with and without HCC.  All patients 
with HCC and esophageal VB admitted between 2007-2010 were included. Follow up was 
prolonged until death, transplantation or 06.2011. For each HCC-patient, a patient without 
HCC matched by age and Child class was selected. 292 patients were included, 146 HCC 
(BCLC class 0-3 patients, A-25, B-29, C-45, D-41) and 146 without HCC. No differences 
were observed regarding prior use of prophylaxis, clinical presentation, endoscopic 
findings, and initial endoscopic treatment. 5-day failure was similar (25% in HCC vs 18% in 
non-HCC, p=0.257). HCC patients had greater 6-week rebleeding rate (16 vs 7%, 
respectively, p=0.025) and 6-week mortality (30% vs 15%, p=0.003). Fewer patients with 
HCC received secondary prophylaxis after bleeding (77% vs 89%, p=0.009) and standard 
combination therapy was used less frequently (58% vs 70%, p=0.079). Secondary 
prophylaxis failure was more frequent (50% vs 31%, p=0.001) and survival significantly 
shorter in patients with HCC (median survival: 5 months Vs greater than 38 months in 
patients without HCC; p<0.001). Lack of prophylaxis increased rebleeding and mortality. 
On multivariate analysis Child score, presence of HCC, portal vein thrombosis and lack of 
secondary prophylaxis were predictors of death. Conclusions: Patients with HCC and 
variceal bleeding have worse prognosis than patients with variceal bleeding without HCC. 
Secondary prophylaxis offers survival benefit in HCC patients.  
 
Page 5 of 37
Hepatology
Hepatology
 5 
 In the last years, there has been an increasing incidence of hepatocellular 
carcinoma1 (HCC). The majority of these tumors develop in patients who have liver 
cirrhosis. The development of HCC has an impact in the natural history of liver disease. In 
a systematic review of studies that evaluated the natural history of cirrhosis, the presence 
of HCC was identified as a predictor of death in 66% of the studies in patients with 
decompensated cirrhosis that included this variable in their analysis 2 . However, an 
increasing variety of therapeutic options are available for patients with HCC 3. Many of 
these options have survival benefit, so it is conceivable that these patients with HCC with 
longer survival, will have greater chances of developing complications of end-stage liver 
disease. 
 Variceal bleeding is one of the complications that characterize decompensated 
cirrhosis. In the last 30 years there has been a substantial improvement in the survival of 
patients with variceal bleeding due to the use of vasoactive drugs, the introduction of 
endoscopic band ligation and the use of antibiotic prophylaxis 4, 5. Presently, further efforts 
are targeted at developing individualized therapeutic strategies in order to adjust the 
approach to the risk the patient has 6, 7. 
 Several prognostic studies have identified the presence of HCC  as a negative 
prognostic factor in variceal bleeding 5, 8, 9. However, many studies in the context of 
variceal bleeding were performed at times when the incidence of HCC was much lower 10, 
11. Furthermore, most observational and experimental studies in the setting of secondary 
prophylaxis excluded patients with HCC 12-25, while other studies have excluded only 
patients with advanced HCC 26-28 or HCC outside of the Milan criteria 6, 29. Therefore it is 
unclear whether or not secondary prophylaxis is useful in these patients. A recent study in 
patients admitted due to variceal bleeding demonstrated greater in-hospital mortality in 
those patients with HCC compared to patients without HCC 9. However this study was 
performed on a large database, based on ICD-9 diagnosis, with the limitations these 
Page 6 of 37
Hepatology
Hepatology
 6 
studies have. Given the lack of information, the management of the acute variceal 
bleeding episode and then the use of secondary prophylaxis in these patients is most 
likely very heterogeneous across different centers. This gap in knowledge is becoming 
increasingly relevant given the rising incidence of HCC, mainly associated to viral 
cirrhosis, which is expected to peak within the next 10 years 30.  Therefore, the aim of this 
study was to evaluate the management and long term outcomes, as defined by rebleeding 
and death, of patients with HCC and esophageal variceal bleeding in comparison to 
patients without HCC.  
 
PATIENTS AND METHODS 
 
 This retrospective observational study was performed in 10 centers in Spain 
[(Hospital Vall d’Hebron (Barcelona), Hospital Clinic (Barcelona),  Hospital Santa Creu i 
Sant Pau (Barcelona), Hospital del Mar (Barcelona), Hospital Germans Trías i Pujol 
(Badalona), Hospital Arnau de Vilanova (Lleida), Hospital Puerta de Hierro (Madrid), 
Hospital Ramón y Cajal (Madrid), Hospital Gregorio Marañón (Madrid),  and Hospital 
Universitario de Canarias (Tenerife)].  Patients meeting the following inclusion criteria were 
included: 1) Acute variceal bleeding episode due to esophageal varices between January 
2007 and December 2010, 2) Liver cirrhosis as diagnosed according to clinical signs, 
laboratory and imaging tests or by liver biopsy. 3) HCC as diagnosed by current criteria1, 
previously known at the time of the variceal bleeding or diagnosed at the time of the 
bleeding episode. Patients with gastrointestinal bleeding not confirmed by diagnostic 
upper gastrointestinal endoscopy were not included.  
 For every patient with esophageal variceal bleeding and HCC, a patient with 
esophageal variceal bleeding without HCC was included. The patients were paired 
according to age (+/- 5  years) and Child-Pugh Class (A/B/C). 
Page 7 of 37
Hepatology
Hepatology
 7 
 Follow-up of all patients was prolonged until June 2011. Patients who received liver 
transplantation during the follow-up were censored at this time point. Data regarding the 
demographics, the liver disease, the bleeding episode and the follow-up were registered. 
In the patients with HCC, information regarding the tumoral disease was collected.  
 Bleeding was considered from esophageal variceal origin when the emergency 
endoscopy, performed within 12 hours after admission, showed any of the accepted 
criteria defining variceal bleeding31. Baveno V definition of events associated to the 
bleeding episode were used: failure to control bleeding, six week rebleeding, six week 
death and failure of secondary prophylaxis, which includes any significant bleeding due to 
portal hypertension after day 5 during the complete follow-up, that leads to hospitalization, 
drop in 3 gr of hemoglobin, blood transfusion or death within six weeks of the rebleeding 
episode32. Previous decompensation was defined by the presence of ascites, hepatic 
encephalopathy or variceal bleeding. 
 
Statistical Analysis.  
 Parametric and non parametric variables are described with means (SD) and 
medians (IQR) respectively. Categorical variables are described with proportions. Chi-
square, student T test, Mann-Whitney U test were used according to variable 
characteristics. Patients who received liver transplantation were censored at the time of 
the transplant. Kaplan-Meier curves were constructed and compared with log-rank test or 
Breslow test as appropriate. Multivariate stepwise Cox regression analysis was performed 
to analyse the independent effect of each variable on survival. The presence of statistical 
and biological interaction and confusion were analysed by stratified analysis and inclusion 
of the product term of the interaction.  The study protocol conformed to the ethical 
guidelines of the 1975 Declaration of Helsinki. Ethics committee approval was obtained.  
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RESULTS 
 During the study period, a total of 146 patients were admitted because of 
esophageal variceal bleeding and HCC in the 10 centers (See appendix 1). The patients 
had a median age of 68 years (IQR 59-74) and were predominantly Child-Pugh class B (A 
30, B 76 and C 40) with a median MELD score of 14 (11-17) (table 1). HCC was 
diagnosed a median of 4 (0-18) months before the variceal bleeding episode. Thirty-seven 
(25%) patients were diagnosed at the time of the bleeding episode while 109 (75%) 
patients were diagnosed previously.  At the time of the variceal bleeding, among HCC 
patients BCLC staging was: 0 in 3 patients, A 27 patients, B 28 patients, C 45 patients, D 
41 patients. Previous treatments performed in these patients were surgery (3 patients), 
radiofrequency ablation (14 patients), percutaneous alcoholization (10 patients), TACE (43 
patients), radioembolization (1 patient) and sorafenib (17 patients).  As planned, 146 
patients who were admitted due to variceal bleeding during the same time period without 
HCC were included with a median age of 67 (56-74) and Child-Pugh class distribution A 
30; B 79; C 37 with a median MELD of 14 (10-17) (p=0.691, in comparison with HCC). 
Expectedly, viral etiology was proportionally more frequent among patients with HCC than 
in the control patients. Furthermore they had more frequently had previous 
decompensation than the control group (73% vs 60%, p=0.025). This finding was 
observed despite the fact that patients were matched by Child-Pugh class and had 
comparable MELD scores. Finally, HCC patients had more frequently portal vein 
thrombosis than control patients. Most patients had not had previous variceal bleeding and 
were eligible for primary prophylaxis (96 in HCC patients, 111 in non HCC patients). From 
these patients, 44 (43%) patients with HCC had primary prophylaxis compared to 40 
(36%) patients without HCC (p=0.186). Similarly, from the patients who were eligible for 
secondary prophylaxis, no significant differences were observed between patients with 
HCC 37/44 (84%)  vs patients without HCC 30/34 (88%) (p=0.755).    
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Management and outcomes of variceal bleed.  
No differences were observed regarding clinical presentation, endoscopic findings and 
initial pharmacological and endoscopic treatment (Table 2). Five-day failure was similar 
(25% and 18% in patients with and without HCC, p=0.257), although more patients with 
HCC died in this time period (11% vs 4 %, p=0.025). Within the first 6 weeks, HCC 
patients had greater rebleeding rate (17% vs 7%, respectively, p=0.022) and mortality 
(30% vs 15%, p=0.003). Significantly fewer HCC patients received secondary prophylaxis 
after bleeding (83% vs 93%, p=0.015) and, among those who received prophylaxis, 
standard therapy (combination of drugs and EBL) was used less frequently (59% vs 70%, 
p=0.098).  As expected, patients with greater BCLC stages (C and D) had less frequently 
secondary prophylaxis (47/71, 66 %), while almost all patients with lower BCLC stages (0, 
A and B) had secondary prophylaxis (55/57, 96%, p<0.001). Overall, lack of secondary 
prophylaxis was significantly associated to 6 week rebleeding (25% of those without 
prophylaxis compared to 9% of patients with prophylaxis, p=0.016) and mortality (59% of 
those without prophylaxis compared to 8% of patients with prophylaxis, p<0.001). Portal 
vein thrombosis (none, benign, malignant respectively) was not associated to 5 day failure 
(20%, 24%, 30%, p=0.385) , although it was associated to 5 day mortality (5%, 0% and 
23%, p<0.001) and 6 week rebleeding (8%, 7%, 29%, p=0.001). 
Long term outcomes  
 No significant differences in rebleeding after 6 weeks were observed between 
patients with and without HCC (19% Vs 17%), p=0.714) (Table 3). However, overall failure 
of secondary prophylaxis was more frequent in patients with HCC than controls (32% Vs 
21%, p=0.05). Expectedly, lack of secondary prophylactic measures was associated with 
secondary prophylaxis failure (data not shown, p<0.001). Similarly, portal vein thrombosis 
was associated with secondary prophylaxis failure (None 25%, benign 21%, malignant 
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35%, <0.001).  During follow-up three patients from each group received liver transplant. 
Most patients without HCC died of decompensated liver disease (40/49), while patients 
with HCC died of decompensated liver disease (34/109), tumoral disease (7/109), or a 
combination of both (61/109). Seven patients from each group had non hepatic deaths. 
 Transplant-free survival was significantly shorter in patients with HCC (median 
survival of 5 months Vs over 38 months in patients without HCC; log rank p<0.001) (figure 
1, panel A). This difference was maintained in each Child-Pugh class (log rank p<0.001) 
(figure 1, panel B-D). Previous decompensation was significantly associated to survival in 
the overall group, however in patients with HCC, no significant differences were observed 
according to this variable (figure 2). Survival curves of patients with HCC according to 
BCLC classification is shown on supplementary figure 1. In order to simplify the statistical 
analysis and according to these survival curves. Patients were divided in 2 groups of 
BCLC classification  (0, A , B and C, D). Expectedly, patients with BCLC 0, A, B had better 
survival rates (median survival 17.3 months, IQR 9.6-36.1)  than patients with BCLC C and 
D (1.5 months, IQR 0.3-3.7), and both groups presented a worse outcome than patients 
without HCC (median survival >60 months), (figure 3).  
 Given the uneven distribution of well known prognostic markers of rebleeding and 
death, multivariate analysis was performed to evaluate the adjusted effect of HCC on 
survival (Table 4A). Even when considering the other variables, HCC and lack of 
secondary prophylaxis remained independent predictors of death.  
 Stratified analysis was performed to evaluate specifically the effect of use of 
secondary prophylaxis in patients according to BCLC. In patients with a BCLC 0, A and B, 
most patients had secondary prophylaxis. However lack of secondary prophylaxis was 
associated to death (log rank <0.001) with a median survival of 0.9 months in patients 
without prophylaxis (2/57, 4 %), compared to 22 months in patients with prophylaxis 55/57, 
96 %).   Similarly in patients BCLC C and D, and despite their dismal prognosis, lack of 
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secondary prophylaxis was also associated to death (log rank <0.001)) with a median 
survival 0.7 months (24/71, 34%), compared to 3 months in patients who had secondary 
prophylaxis (47/71, 66%) (figure 4).  
 A second model was performed in order to analyse the predictors of death in the 
subpopulation of patients with HCC and specifically the impact of the use of secondary 
prophylaxis taking into account BCLC classification stage. In this multivariate analysis 
Child-Pugh score, portal vein thrombosis, BCLC classification and use of secondary 
prophylaxis remained independent predictors of death (Table 4B). When the independent 
predictors of failure of secondary prophylaxis were evaluated, only BCLC classification 
[HR 1.78 (95% CI 1.23-2.59)], presence of portal vein thrombosis [benign HR 1.70 (95% 
CI 0.61-4.74), malignant 4.62 (95%CI 1.96-10.90)] and use of secondary prophylaxis  [HR 
0.33 (95% CI 0.14-0.75)] were independently associated with the outcome.  
 Taking into account that the differences in the use of secondary prophylaxis were 
mainly in the patients with BCLC C and D, further analysis was performed to compare 
these patients with and without prophylaxis (See Suppl Table 1). Patients who received no 
prophylaxis had more severe liver disease as shown by greater Child-Pugh score and 
MELD score, although there were no differences in the severity of the HCC as shown by 
the proportion of patients with BCLC C or D, portal vein thrombosis or metastasis.  
 
DISCUSSION  
 
 In this study, a significantly lower survival rate was observed in patients who had 
HCC at the time of bleeding than patients who did not have HCC, despite the fact that the 
patients were matched for Child-Pugh class and age. This issue is of utmost interest as 
many studies that evaluated the treatment of acute bleeding episode and prophylaxis of 
rebleeding had excluded patients with HCC12-25. Furthermore, given the increasing 
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incidence of HCC, due to rising hepatitis C virus associated advanced liver disease, which 
is expected to peak in 2020, HCC and variceal bleeding are an increasingly common 
clinical problem that clinicians have to deal with. On the other hand, with further 
improvement in the management of patients with HCC with survival benefit 33-37 , these 
patients have more probabilities to present with complications of end stage liver disease. A 
previous study based on ICD-09 diagnostic codes suggested similar results, although due 
to the design of the study no in depth analysis could be performed 9. 
 Interestingly patients with HCC were less likely to have secondary prophylaxis than 
patients without HCC and a trend for a less frequent use of standard secondary 
prophylaxis with combination of betablockers and endoscopic band ligation in those 
patients with HCC. The reason why HCC patients were not offered standard therapy is 
unclear from this study. It is likely that this was due to the assumption by the attending 
physician that this would not result in a clinical benefit. This is also suggested by the fact 
that patients with HCC without secondary prophylaxis seemed to have more severe liver 
disease. However, as lack of secondary prophylaxis was associated to a greater 
probability of failure and death in models adjusted for severity of liver disease, our results 
support offering patients with HCC the same treatment after variceal bleeding as it is done 
for patients without HCC. Although there were no differences in rebleeding rate after 6 
weeks when comparing HCC to non-HCC patients, more patients with HCC died in this 
time period.  Indeed, most patients with HCC who died, died of progressive tumoral 
disease and decompensated liver disease. In addition, when the specific predictors of 
failure of secondary prophylaxis and death were evaluated in patients with HCC including 
BCLC classification, the use of secondary prophylaxis had an independent protective 
effect on the development of rebleeding and death, further suggesting that use of this 
treatment should be prolonged as long as the clinical condition of the patient allows it. 
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 Despite the fact that the groups were matched by Child-Pugh class and had similar 
MELD score, patients with HCC had more frequently previous decompensation than 
patients without HCC. Belonging to the compensated or decompensated phase of the liver 
disease is of utmost relevance given the well known survival differences between these 
groups2. Indeed, after introduction of MELD score, it had been remarked that different 
survival rates could be seen in patients with the same MELD score according to the 
presence or absence of clinical decompensation 38 . In the present study, it should be 
underlined that from the moment they experience variceal bleeding, all patients are in the 
decompensated phase. For this reason this variable was not chosen initially as a matching 
variable. Also,  as expected, patients with HCC had more commonly a viral etiology of their 
liver disease. Viral etiology has been identified as a negative prognostic factor for 5 day 
failure in acute variceal bleeding 29. Given the possible confusion that these variables could 
introduce, they were included in the multivariate analysis. On multivariate analysis both the 
etiology of liver disease and the presence of previous decompensation were not identified 
as independent predictors of survival.  
 Portal vein thrombosis was also distributed unevenly between patients with HCC 
and control patients. This variable was significantly associated with outcomes of variceal 
bleeding and survival. Previous studies have associated the presence of portal vein 
thrombosis with negative outcomes in variceal bleeding39. Interestingly, the prognostic 
information derived from the presence of portal vein thrombosis was independent from the 
BCLC classification.  
 Among patients with HCC, survival was mainly influenced by disease stage, best 
described by the BCLC classification. So patients in class C and D had a much greater 
likelihood of dying within 6 months (79%) compared to class 0, A and B (14%)   
Nevertheless, lack of secondary prophylaxis was an independent predictor of death taking 
into account BCLC classification. Therefore use of secondary prophylaxis in these 
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patients, even in those with the most advanced tumoral disease (BCLC C and D), had 
survival advantages. Logically, patients with less advanced tumors are the ones who have 
the most to benefit from the use of secondary prophylaxis. Physicians taking care of 
patients with advanced HCC after a variceal bleeding episode should individualize 
therapies according to clinical practice, common sense and patient needs. Some may 
judge that the survival benefit in these BCLC C and D patients who received secondary 
prophylaxis is not clinically relevant (average 3 months) and that more interventional 
therapies (banding ligation) should be avoided taking into account the possible adverse 
effects.. Nevertheless, this survival benefit is similar to the survival benefit offered with 
sorafenib treatment in BCLC C patients, which also has side effects, which may impact 
quality of life. The present study showing a global survival effect of prophylaxis patients 
with advanced HCC, provides further evidence to indicate prophylaxis in this subgroup of 
patients as long as their clinical condition allows to do so. 
 There are several setbacks to the study. Some patients with very advanced HCC 
and upper gastrointestinal bleeding were not included in the study as no endoscopy was 
performed.  This could lead to some bias in the results, as it is probable that these patients 
who were not included would be the ones who would be most likely to die. However, the 
decision to exclude these patients from the study was based on several reasons. Firstly, 
although suspected, the cause of the bleeding was not proven as endoscopy was not 
performed. It is well established that about one third of upper gastrointestinal bleeding 
episodes in patients with cirrhosis are due to other causes rather than esophageal 
varices40, 41. Secondly, most likely the patients who would not receive endoscopy would 
probably be the sickest ones and therefore with the most dismal outcome. Therefore 
inclusion of these patients in the analysis might further enhance the differences in the 
outcomes of variceal bleeding in patients with and without HCC. Furthermore, and 
although it seems that patients with HCC without secondary prophylaxis were more sick 
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than the ones who received secondary prophylaxis,which may have influenced the 
physicians opinion, it could be that there are other factors that influenced this decision that 
are not included in the analysis. Unfortunately, the study design does not allow analysis of 
the impact of sorafenib treatment on variceal bleeding. It has been establshed both in 
animal and human studies that sorafenib has a portal hypotensive effect, perhaps through 
an inhibition of angiogenesis42, 43. Therefore, there could be an impact of the administration 
of this drug on the outcomes. In the present study, sorafenib was administered exclusively 
to patients with advanced HCC, therefore it is logical to speculate that lack of sorafenib 
could further worsen the outcome of these patients, who already have a dismal prognosis. 
Another limitation of the study is the uneven distribution of the etiologies among patients 
with and without HCC. Although on multivariate analysis viral disease was not identified as 
an independent predictor of death (and therefore non-viral disease, which was mainly 
alcohol, was not identified as a predictor of survival), it could be that non-HCC patients 
with alcoholic liver disease ceased alcohol consumption after the variceal bleed and 
therefore had a better outcome. Finally, the design of this study does not allow evaluation 
of the impact of variceal bleeding in the natural history of HCC.  
 In conclusion patients with HCC with variceal bleed have worse outcomes than 
patients without HCC. These differences are only partially explained by differences in 
secondary prophylaxis measures, as in patients with variceal hemorrhage and HCC. Use 
of secondary prophylaxis has survival benefit in patients with HCC irrespective of BCLC 
stage.
Page 16 of 37
Hepatology
Hepatology
 16 
Bibliografía 
1. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 
2005;42:1208-36. 
2. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of 
survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31. 
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. 
Hepatology 2011;53:1020-2. 
4. Graham DY, Smith JL. The course of patients after variceal hemorrhage. 
Gastroenterology 1981;80:800-9. 
5. D'Amico G, De Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic 
outcome and prognostic indicators. Hepatology 2003;38:599-612. 
6. Garcia-Pagan JC, Caca K, Bureau C, et al. Early use of TIPS in patients with 
cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370-9. 
7. Augustin S, Millan L, Gonzalez A, Coll M, Martell M, Genesca J. Prognostic 
evaluation of patients with acute variceal bleeding. Dis Markers 2011;31:155-64. 
8. Augustin S, Muntaner L, Altamirano JT, et al. Predicting early mortality after acute 
variceal hemorrhage based on classification and regression tree analysis. Clin 
Gastroenterol Hepatol 2009;7:1347-54. 
9. Singal AK, Jampana SC, Singal V, Kuo YF. Hepatocellular carcinoma predicts in-
hospital mortality from acute variceal hemorrhage among patients with cirrhosis. J 
Clin Gastroenterol 2012;46:613-9. 
10. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United 
States. N Engl J Med 1999;340:745-50. 
11. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 
1998;351:214-5. 
12. Garcia-Pagan JC, Morillas R, Banares R, et al. Propranolol plus placebo versus 
propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: 
a double-blind RCT. Hepatology 2003;37:1260-6. 
13. Garcia-Pagan JC, Villanueva C, Vila MC, et al. Isosorbide mononitrate in the 
prevention of first variceal bleed in patients who cannot receive beta-blockers. 
Gastroenterology 2001;121:908-14. 
14. Lo GH, Chen WC, Chen MH, et al. Endoscopic ligation vs. nadolol in the prevention 
of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 2004;59:333-
8. 
15. Lo GH, Chen WC, Wang HM, Lee CC. Controlled trial of ligation plus nadolol versus 
nadolol alone for the prevention of first variceal bleeding. Hepatology 2010;52:230-
7. 
16. Lo GH, Lai KH, Cheng JS, Chen MH, Chiang HT. A prospective, randomized trial of 
butyl cyanoacrylate injection versus band ligation in the management of bleeding 
gastric varices. Hepatology 2001;33:1060-4. 
17. Lo GH, Lai KH, Cheng JS, Lin CK, Hsu PI, Chiang HT. Prophylactic banding ligation 
of high-risk esophageal varices in patients with cirrhosis: a prospective, randomized 
trial. J Hepatol 1999;31:451-6. 
18. Escorsell A, Ruiz del Arbol L, Planas R, et al. Multicenter randomized controlled trial 
of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the 
TEST study. Hepatology 2000;32:471-6. 
19. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper 
gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. 
Gastroenterology 2004;127:1123-30. 
20. Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the 
prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 
2004;127:476-84. 
Page 17 of 37
Hepatology
Hepatology
 17 
21. Merkel C, Marin R, Enzo E, et al. Randomised trial of nadolol alone or with 
isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. 
Gruppo-Triveneto per L'ipertensione portale (GTIP). Lancet 1996;348:1677-81. 
22. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal 
hypertension and its early decompression by TIPS placement on the outcome of 
variceal bleeding. Hepatology 2004;40:793-801. 
23. Sarin SK, Lamba GS, Kumar M, Misra A, Murthy NS. Comparison of endoscopic 
ligation and propranolol for the primary prevention of variceal bleeding. N Engl J 
Med 1999;340:988-93. 
24. Sarin SK, Wadhawan M, Agarwal SR, Tyagi P, Sharma BC. Endoscopic variceal 
ligation plus propranolol versus endoscopic variceal ligation alone in primary 
prophylaxis of variceal bleeding. Am J Gastroenterol 2005;100:797-804. 
25. Villanueva C, Planella M, Aracil C, et al. Hemodynamic effects of terlipressin and 
high somatostatin dose during acute variceal bleeding in nonresponders to the 
usual somatostatin dose. Am J Gastroenterol 2005;100:624-30. 
26. Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate 
compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J 
Med 1996;334:1624-9. 
27. Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined 
treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal 
bleeding. N Engl J Med 2001;345:647-55. 
28. Schepke M, Kleber G, Nurnberg D, et al. Ligation versus propranolol for the primary 
prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004;40:65-72. 
29. Abraldes JG, Villanueva C, Banares R, et al. Hepatic venous pressure gradient and 
prognosis in patients with acute variceal bleeding treated with pharmacologic and 
endoscopic therapy. J Hepatol 2008;48:229-36. 
30. Mair RD, Valenzuela A, Ha NB, et al. Incidence of Hepatocellular Carcinoma 
Among US Patients With Cirrhosis of Viral or Nonviral Etiologies. Clin Gastroenterol 
Hepatol 2012. 
31. de Franchis R, Pascal JP, Ancona E, et al. Definitions, methodology and 
therapeutic strategies in portal hypertension. A Consensus Development Workshop, 
Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol 1992;15:256-61. 
32. de Franchis R. Revising consensus in portal hypertension: report of the Baveno V 
consensus workshop on methodology of diagnosis and therapy in portal 
hypertension. J Hepatol 2010;53:762-8. 
33. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation 
versus symptomatic treatment in patients with unresectable hepatocellular 
carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9. 
34. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular 
carcinoma. N Engl J Med 2008;359:378-90. 
35. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment 
for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in 
Japan. The Liver Cancer Study Group of Japan. Hepatology 2000;32:1224-9. 
36. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves 
prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. 
Gastroenterology 2004;127:1714-23. 
37. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small 
hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol 
injection. Radiology 1999;210:655-61. 
38. Said A, Williams J, Holden J, et al. Model for end stage liver disease score predicts 
mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897-903. 
Page 18 of 37
Hepatology
Hepatology
 18 
39. Amitrano L, Guardascione MA, Manguso F, et al. The effectiveness of current acute 
variceal bleed treatments in unselected cirrhotic patients: refining short-term 
prognosis and risk factors. Am J Gastroenterol 2012;107:1872-8. 
40. Pinto HC, Abrantes A, Esteves AV, Almeida H, Correia JP. Long-term prognosis of 
patients with cirrhosis of the liver and upper gastrointestinal bleeding. Am J 
Gastroenterol 1989;84:1239-43. 
41. Christensen E, Fauerholdt L, Schlichting P, Juhl E, Poulsen H, Tygstrup N. Aspects 
of the natural history of gastrointestinal bleeding in cirrhosis and the effect of 
prednisone. Gastroenterology 1981;81:944-52. 
42. D'Amico M, Mejias M, Garcia-Pras E, et al. Effects of the combined administration 
of propranolol plus sorafenib on portal hypertension in cirrhotic rats. Am J Physiol 
Gastrointest Liver Physiol 2012;302:G1191-8. 
43. Pinter M, Sieghart W, Reiberger T, Rohr-Udilova N, Ferlitsch A, Peck-Radosavljevic 
M. The effects of sorafenib on the portal hypertensive syndrome in patients with 
liver cirrhosis and hepatocellular carcinoma--a pilot study. Aliment Pharmacol Ther 
2012;35:83-91. 
Page 19 of 37
Hepatology
Hepatology
 19 
Figure legends:  
 
 
Figure 1: Survival curves of patients after variceal bleeding with hepatocellular carcinoma 
(dotted line) compared to patients without hepatocellular carcinoma (continuous 
line) (Panel A) and according to Child-Pugh class. Panel B: Child-Pugh class A, 
Panel C: Child-Pugh class B, Panel D: Child-Pugh class C. Log rank test p< 0.001 
 
Figure 2: Survival curves of patients after variceal bleeding according to the presence 
(dotted line) or absence (continuous line) of prior clinical decompensation (Panel A). 
Log rank test p< 0.001. Subanalysis in patients with hepatocellular carcinoma 
according to the presence (dotted line) or absence (continuous line) of prior clinical 
decompensation (Panel B) Log rank test  p=0.231. 
 
Figure 3: Survival curves of patients after variceal bleeding with hepatocellular carcinoma 
according to BCLC stage (0, A, B: short dotted line; C,D: long dotted line) compared 
to patients without hepatocellular carcinoma (continuous line). Breslow test p < 
0.001  
 
Figure 4: Survival curves of patients after variceal bleeding with hepatocellular carcinoma 
BCLC C and D according to presence (continuous line) or absence (dotted line) of 
secondary prophylaxis. Log rank p< 0.001 
 
 
Supplementary Figure 1: Survival curves of patients after variceal bleeding with 
hepatocellular carcinoma according to BCLC stage (curves identified on the graph) 
compared to patients without hepatocellular carcinoma (continuous line). Breslow 
test p< 0.001 
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Table 1. Baseline characteristics 
 
 
 
Variables are presented in proportion or medians (IQR). Denominator of the 
proportions is the number of patients in the group unless otherwise stated. Chi-
square and Mann-Whitney U tests were used as appropriate. Proportions of 
primary and secondary prophylaxis are calculated according to the number of 
eligible patients.  
 
Abbreviations: HCC: Hepatocellular carcinoma, HCV: Hepatitis C virus, HBV: 
Hepatitis B virus, HIV: human immunodeficiency virus, MELD: Model for End 
 Non HCC patients 
n=146 
HCC patients 
n=146 
p value 
Male 101 (69%) 116 /79%) 0.060 
Age (yrs) 67 (56-74) 68 (59-74) 0.778 
Etiology 
           Alcohol 
           Alcohol + HCV 
           HCV 
           HBV 
           Others 
 
62 (42%) 
15 (10%) 
43 (29%) 
6 (4%) 
20 (14%) 
 
37 (25%) 
20 (14%) 
71(49%) 
11 (8%) 
7 (5%) 
<0.001 
HIV infection 4 (3%) 9 (6%) 0.165 
Child-Pugh Class  
            A  
            B 
            C  
 
30 (21%) 
79 (54%) 
37 (25%) 
 
30 (21%) 
76 (52%) 
40 (27%) 
0.797 
MELD  14(10-17) 14(11-17) 0.691 
Previous decompensation 
           Total 
           Variceal bleeding 
           Ascites 
           Hepatic  Encephalop. 
 
88 (60%) 
31 (21%) 
78 (53%) 
19 (13%) 
 
107 (73%) 
43 (29%) 
95 (65%) 
22 (16%) 
 
0.025 
0.139 
0.057 
0.737 
Bilirubin (mg/dL) 1.6 (1.1-2.4) 1.5 (1-3.0) 0.985 
INR 1.4 (1.3-1.7) 1.4 (1.3-1.6) 0.155 
Albumin (g/dL 2.8 (2.4-3.3) 2.9 (2.5-3.3) 0.431 
Creatinine (mg/dL) 0.9 (0.7-1.2) 1.0 (0.8-1.3) 0.025 
Previous Primary 
Prophylaxis* 
40/112 (36%) 44/102 (43%) 0.186 
Previous Secondary 
Prophylaxis* 
30/34 (88%) 37/44(84%) 0.755 
 Time from HCC diagnosis 
(months) 
- 4 (0-18) 
 
- 
BCLC 0/A/B/C/D - 3/27/28/45/41 - 
Portal vein thrombosis 
           None 
           Benign 
           Malignant 
 
137 (94%) 
9 (6%) 
0 
 
78 (53%) 
20 (14%) 
48 (33%) 
<0.001 
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stage Liver Disease, Hepatic Encephalop: Hepatic Encephalopathy. BCLC: 
Barcelona Clínic Liver Cancer Classification 
 
Page 22 of 37
Hepatology
Hepatology
Table 2. Characteristics of Variceal Bleeding and Outcomes (according to 
Baveno) 
 
 
Variables are presented in proportions. The denominator of the proportions is 
the number of patients in the group in whom the information was available or 
applicable* unless otherwise stated.  Small varices are Grade I, large varices 
are > Grade I varices. Chi-square tests were applied.  
 
Abbreviations: HCC: Hepatocellular carcinoma, EBL: Endoscopic band ligation, 
SMT: somatostatin, Ceph 3rd Gen: 3rd generation cephalosporins 
 
 
 Non HCC patients 
n=146 
HCC patients 
n=146 
p value 
Shock at presentation 43 (29%) 32 (22%) 0.141 
Infection  15/145 (10%) 21 (14%) 0.295 
Size of varices 
    Small 
    Large 
 
10 (7%) 
136 (93%) 
 
11 (8%) 
133 (92%) 
0.795 
Bleeding signs at 
endoscopy 
    None 
    Nipple 
    Oozing 
     Jet 
 
 
75 (51%) 
38 (26%) 
16 (11%) 
17 (12%) 
 
 
75/141 (53%) 
35/141 (25%) 
19/141 (13%) 
12/141 (9%) 
0.764 
Initial endoscopic 
treatment 
   None 
   Sclerotherapy 
   EBL 
   Glue  
 
 
9 (6%) 
22 (15%) 
114 (78%) 
1 (1%) 
 
 
18 (12%) 
20 (14%) 
105 (72%) 
3 (2%) 
0.215 
Initial pharmacological 
therapy 
   None 
   SMT (6 mg/24h) 
   SMT (12 mg/24h) 
   Terlipressin 
 
 
1 (1%) 
93 (64%) 
50 (34%) 
2 (1%) 
 
 
2 (1%) 
93 (64%) 
48 (33%) 
2 (1%) 
0.946 
Antibiotic prophylaxis 
   None 
   Ceph. 3rd Gen 
   Quinolones 
 
3/142 (2%) 
112/142 (79%) 
27/142 (19%) 
 
5/140 (4%) 
111/140 (79%) 
24/140 (17%) 
0.860 
Balloon tamponade 2 (1%) 3 (2%) 0.652 
Initial control of bleeding 129/135 (96%) 131 (90%) 0.271 
5 day failure 27 (18%) 37 (25%) 0.257 
5 day death  6 (4%) 16 (11%) 0.044 
6 week rebleeding* 10/140 (7%) 22/130(17%) 0.023 
6 week death 22 (15%) 44 (30%) 0.003 
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Tabla 3. Long-term outcomes 
 
 
Patients who died within the first 5 days are excluded. Variables are presented 
in proportion or medians (IQR). The denominator of the proportions is the 
number of patients in the group unless otherwise stated. Chi-square, Mann-
Whitney U and log-rank tests were used as appropriate. * Proportions are 
calculated according to the number of eligible patients, that is the patients who 
were still alive 6 weeks after the original bleeding episode. 
 
Abbreviations: HCC: Hepatocellular carcinoma, 6w: 6 weeks 
 Non HCC patients 
n=140 
HCC patients 
n=130 
p value 
Follow up 
(months) 
11.6 (2.7-24.9) 3.3 (0.6-13.4) <0.001 
Rebleeding (> 6w)* 19/112 (17%) 18/94 (19%) 0.718 
Failure of 
secondary 
prophylaxis 
29 (21%) 41 (32%) 0.05 
Liver 
Transplantation 
3 (2%) 3 (2%) 0.675 
Death 49 (35%) 109 (84%) <0.001 
Transplant-free 
survival (months) 
>38 (6.4-not 
calculable) 
5.0 (0.8-17.3) <0.001 
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Table 4A. Uni- and Multivariate Cox analysis of predictors of death 
 
Variable Univariate HR (95% CI) Adjusted HR (95% CI) 
HCC 3.35 (2.38-4.71) 5.45 (2.69-11.05) 
MELD 1.11 (1.08-1.14) - 
Previous decompensation 1.99 (1.38-2.86) - 
Lack of Secondary 
prophylaxis 
6.67 (4.54-10.00) 6.67 (4.16-11.11) 
Etiology* 2.09 (1.49-2.92) - 
Child-Pugh class 
   -A (reference) 
   -B 
   -C 
 
- 
1.48 (0.94-2.32) 
3.30 (2.04-5.32) 
 
- 
 
Child-Pugh score 1.23 (1.14-1.33) 1.28 (1.15-1.42) 
Portal vein thrombosis 
   -none (reference) 
   -benign 
   -malignant 
 
- 
0.99 (0.55-1.76) 
5.68 (3.62-8.92) 
 
- 
1.41 (0.75-2.62) 
3.29 (2.03-5.33) 
Sex 1.07 (0.75-1.54) - 
Age 1.01 (0.99-1.02) - 
Bilirubin 1.08 (1.03-1.13) - 
Albumin  1.01 (0.99-1.03) - 
INR  2.22 (1.49-3.30) - 
Creatinine 1.33 (1.21-1.46) - 
Standard prophylaxis 0.83 (0.56-1.24) - 
 
 
Multivariate stepwise Cox regression analysis to evaluate the independent 
predictors of death (n=142). Etiology was recoded in two categories (non viral, 
which was the reference category, and viral disease).  Variables initially 
included in the multivariate analysis: age, HCC, MELD, previous 
decompensation, secondary prophylaxis, etiology, portal vein thrombosis and 
Child Pugh Score. Variables included in MELD score were not included in the 
multivariate analysis to avoid colinearity. Child-Pugh class was not included due 
to the fact that this was a matching variable. 
 
Table 4B. Multivariate predictors of death among HCC patients.  
 
Multivariate stepwise Cox regression analysis to evaluate the independent 
predictors of death (n=99). Variables initially included in the multivariate 
Variable 95% CI 
BCLC Classification 4.04 (2.24-7.27) 
Lack of secondary prophylaxis 4.00 (2.27-6.67) 
Child-Pugh Score 1.29(1.15-1.44) 
Portal vein thrombosis 
     -none (reference) 
     -benign 
     -malignant 
 
- 
0.90 (0.42-1.96) 
2.16 (1.27-3.68) 
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analysis: BCLC (classified in two categories: 0.A, B and C, D), previous 
decompensation, secondary prophylaxis, etiology, Child-Pugh score and portal 
vein thrombosis.  
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Appendix 1: Patient distribution according to centers.  
 
Center Number of Patients (HCC/nonHCC) 
Canarias 6/6 
LLeida 9/9 
Clínic 32/32 
Sta Creu St. Pau 17/17 
Vall D’Hebron 17/17 
Ramon y Cajal 14/14 
Gregorio Marañón 26/26 
Germans Trias i Pujol 7/7 
Hospital del Mar 12/12 
Puerta de Hierro 6/6 
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Suplementary Table 1. Comparison of BCLC  C and D with and without 
secondary Prophylaxis   
 
 
 Patients without 
Prophylaxis 
(n=24) 
Patients with 
secondary 
Prophylaxis 
(n=47) 
p-value 
Male 20 (83) 39 (83) 1 
Age (yrs) 74 (60-77) 65 (59-73) 0.038 
Child-Pugh 
score 
9 (7-10) 8 (7-9) 0.052 
MELD  16 (15-22) 13(10-17) 0.001 
BCLC  
C  
D  
 
13 (54) 
11 (46) 
 
28 (60) 
19 (40) 
0.800 
Time of 
diagnosis 
(months)  
7 (0-24) 4 (0-22) 0.743 
Follow-up 
(months)  
0.6 (0.3-1.7) 2.6 (1.1-5.0) <0.001 
Etiology 
Alcohol  
Virus  
 
7 (29) 
17 (71) 
 
11 (23) 
36 (77) 
0.774 
Previous Ascites  19 (79) 26 (55) 0.041 
Previous 
Hepatic 
Encephalopathy  
7 (29) 6 (13) 0.088 
Previous 
Variceal 
Bleeding  
6 (25) 15 (32) 0.376 
Previous 
Decompensation 
19 (79) 32 (68) 0.244 
Portal Vein 
Thrombosis 
No  
Benign  
Malignant  
 
 
13 (54) 
2 (8) 
9 (38) 
 
 
14 (30) 
8 (17) 
25 (53) 
0.085 
Metastases  3 (13) 4 (9) 0.676 
Bilirubin (mg/dL) 2.2 (1.4-3.5) 1.3 (1-2.2) 0.035 
INR 1.45 (1.29-1.72) 1.33 (1.24-1.50) 0.215 
Albumin (gr/dL) 3.0 (2.4-3.6) 2.9 (2.5-3.3) 0.626 
Creatinin 
(mg/dL) 
1.3 (0.9 -2.0) 0.9 (0.7-1.3) 0.002 
Bleeding at 
endoscopy  
13 (54) 19 (40) 0.237 
Hypovolemic 
shock  
4 (17) 7 (15) 1 
Balloon 0 0  
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Tamponade 
Infection  4 (17) 9 (19) 1 
Rebleeding <6 
weeks 
8 (33) 10(21) 0.260 
Mortality <6 
weeks 
18 (75) 8 (17) <0.001 
Failure of 
secondary 
prophylaxis 
20 (83) 15 (32) <0.001 
Rebleeding >6 
weeks 
2(8) 7 (15) 0.708 
Mortality at 3 
months 
21 (88) 19 (40) <0.001 
Mortality at 6 
months 
23 (96) 30 (64) 0.003 
Mortality at 1 
year 
23 (96) 35 (74) 0.641 
Mortality at end 
of follow-up 
24 (100) 38 (81) 0.024 
 
Variables are presented in proportion or medians (IQR). Chi-square and Mann-
Whitney U tests were used as appropriate. 
Abbreviations: HCC: Hepatocellular carcinoma, MELD: Model for End stage 
Liver Disease, BCLC: Barcelona Clínic Liver Cancer Classification 
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